Prevention of angiogenesis by naked DNA IL-12 gene transfer: Angioprevention by immunogene therapy

Gene Therapy

Volumn 11, Issue 3, 2004, Pages 284-291

  Morini, M ^a   Albini, A ^a   Lorusso, G ^a   Moelling, K ^b   Lu, B ^c   Cilli, M ^a   Ferrini, S ^a   Noonan, D M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Interferon gamma; Interleukin 12; Kaposi's sarcoma; Naked DNA; Tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR3; CXC CHEMOKINE RECEPTOR 3; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; MATRIGEL; NAKED DNA; PLASMID DNA; PLASMID VECTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER PREVENTION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOGENETICS; IMMUNOLOGY; IN VIVO STUDY; KAPOSI SARCOMA; KNOCKOUT MOUSE; MALE; METHODOLOGY; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NATURAL KILLER CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PATHOLOGY; PLASMID; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULARIZATION;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; RECEPTORS, CHEMOKINE; SARCOMA, KAPOSI; T-LYMPHOCYTES;

ANIMALIA; MURINAE; MUS MUSCULUS; VECTORS;

EID: 1242296137     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302175     Document Type: Article

References (36)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
4. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16: 2-14.
5. Wolf SF et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074-3081.
6. McKnight AJ et al. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 1994; 152: 2172-2179.
7. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-276.
8. Heinzerling L et al. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. Exp Dermatol 2002; 11: 232-240.
9. Schultz J et al. Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. Hum Gene Ther 1999; 10: 407-417.
10. Schultz J, Pavlovic J, Moelling K. Immune modulation in cancer using DNA inoculation - antitumour effect of interleukin-12. Dev Biol 2000; 104: 109-114.
11. Perez-Diez A, Marincola FM. Immunotherapy against antigenic tumors: a game with a lot of players. Cell Mol Life Sci 2002; 59: 230-240.
12. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168.
13. Cavallo F et al. Prevention by delay: nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice. J Biol Regul Homeost Agents 2001; 15: 351-358.
14. Boggio K et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 2000; 60: 359-364.
15. Kanegane C et al. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 1998; 64: 384-392.
16. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877-3882.
17. Strasly M et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001; 166: 3890-3899.
18. Cavallo F et al. Interleukin 12-activated lymphocytes influence tumor genetic programs. Cancer Res 2001; 61: 3518-3523.
19. Miller M. KS enters Y2K still riddled with many questions. J Natl Cancer Inst 1999; 91: 1612-1614.
20. Forni G, Lollini PL, Musiani F, Colombo MP. Immunoprevention of cancer: is the time ripe? Cancer Res 2000; 60: 2571-2575.
21. Scapini P et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002; 168: 5798-5804.
22. Schultz J, Heinzerling L, Pavlovic J, Moelling K. Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. Cancer Gene Ther 2000; 7: 1557-1565.
23. Li S, Xia X, Zhang X, Suen J. Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Therapy 2002; 9: 390-397.
24. Stylianou E et al. Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients. Clin Exp Immunol 2002; 130: 279-285.
25. Murphy PM et al. International union of pharmacology XXII. Pharmacol Rev 2000; 52: 145-176.
26. Hancock WW et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515-1520.
27. Trinchieri G, Scott P. Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999; 238: 57-78.
28. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70: 83-243.
29. Cavallo F et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 1999; 59: 414-421.
30. Pertl U et al. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001; 166: 6944-6951.
31. Comes A et al. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. Eur J Immunol 2002; 32: 1914-1923.
32. Cifaldi L et al. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 2001; 61: 2809-2812.
33. Di Carlo E et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 2000; 165: 3111-3118.
34. Albini A et al. Angiogenic potential in vivo by Kaposi sarcoma cell-free supernatants and HIV1-tat product: inhibition of KS-like lesions by TIMP-2. AIDS 1994; 8: 1237-1244.
35. Meazza R et al. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 2000; 87: 574-581.
36. Albini A et al. The beta-core fragment of human Chorionic Gonadotrophin (hCG) inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS 1997; 11: 713-721.